The LuCaRE study investigated real-world treatment patterns and clinical outcomes in a cohort of 110 patients diagnosed with advanced-stage NSCLC and EGFR mutations at a tertiary comprehensive institute. Here, EGFR is linked to non-small cell lung carcinoma.